Inflammation and Salt-inducible kinases in heart failure V1

  • Research type

    Research Study

  • Full title

    Inflammation and Salt-inducible kinases - A potential Novel therapeutic strategy in patients with heart failure.

  • IRAS ID

    304359

  • Contact name

    Ify Mordi

  • Contact email

    I.mordi@dundee.ac.uk

  • Sponsor organisation

    TASC

  • Duration of Study in the UK

    1 years, 7 months, 30 days

  • Research summary

    Heart failure (HF) is a complex clinical syndrome characterized by multiple debilitating symptoms, such as fatigue, pain, ankle swelling, and breathlessness. HF is categorized according to left ventricular ejection fraction (LVEF) into HF with reduced ejection fraction (HFrEF) (usually considered LVEF 40% or less) and HF with preserved ejection fraction (HFpEF). Systemic inflammation has been shown to be implicated in both types of heart failure via Pro-inflammatory cytokines that are regulated by Salt-inducible kinases SIKS. our study will investigate HF, cardiac structural, and functional parameters in responses to SIK activity. The aim of this study is to assess the role of SIK-related inflammation in heart failure. We will perform an observational pilot study of 100 patients with stage B or C HF. Stage B includes patients with structural heart disease but without signs and symptoms of HF while stage C encompasses patients who have structural heart disease with prior or current symptoms of HF HF. Blood samples will be taken at baseline as well as a quality of life questionnaire (Kansas City Cardiomyopathy Questionnaire). The first group of the baseline samples will be taken within 36 hours of admission whereas the second group of the baseline samples will be obtained on day 5 of admission unless the patients are discharged earlier. In patients where there has not been a recent heart scan (echocardiography), this will also be performed). 40 patients will return for a further assessment at 6 months where these tests will be repeated.

    We will measure levels of inflammation (specifically SIKs) in the patients with HF and correlate these with heart function and quality of life..

  • REC name

    West of Scotland REC 1

  • REC reference

    21/WS/0161

  • Date of REC Opinion

    15 Dec 2021

  • REC opinion

    Unfavourable Opinion